Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (832)	9/24/2001 10:45:53 AM
From: tuck	Respond to of 1784

Good news from CRL again. They and BDAL are the trickle kings when it comes to maintaining or upwardly revising forecasts. How much longer can all this good news last? Do they not ship the mice by air? >>WILMINGTON, Mass., Sept 24 (Reuters) - Charles River Laboratories International Inc. (NYSE:CRL - news) on Monday raised its third-quarter earnings and revenue forecast, due in part to strong growth across most of its product lines. The company, which provides rats and mice for drug research, expects third-quarter earnings per share of 25 or 26 cents, up from an earlier projection of 21 to 22 cents per share. Analysts' consensus estimate is 22 cents, according to Thomson Financial/First Call. Charles River also said it expects third-quarter sales to slightly exceed the high end of the earlier forecast range of $114 million to $117 million. ``With most of the third quarter now complete, we're pleased to once again see better than anticipated revenue growth and earnings strength in most of our product lines and services offerings, along with an improved income tax rate,'' said James Foster, chief executive of Charles River. Foster cited strong performance from two new acquisitions, and in Charles River's core U.S. business and operations in Japan and Europe.<< snip Cheers, Tuck